We now have identified that the mTOR inhibitor TEMS alters LD quality in both RCC and normal immortalized HK-2 cells, possibly to enhance lipid mobilization, which antagonizes cellular sensitivity to the treatment (Figs 2B and 3A). This evidence concerns the gene MTOR and renal cell adenocarcinoma.